{ "items": [ "\n\n
\n \n 14 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 29 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n \n \n QResearch\n \n \n\n \n\n\n
\n \n\n \n \n \nThe first large study to report the effect of bodyweight on risk of worse outcomes from COVID-19 across the full range of body mass index (BMI) is published today in The Lancet Diabetes and Endocrinology journal.
\n \n\n\n \n 16 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 12 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nInhaled budesonide, a common corticosteroid, is the world's first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. As of today, the treatment is available in UK primary care on a case-by-case basis.
\n \n\n\n \n 8 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nCould the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
\n \n\n\n \n 2 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Cardiovascular & metabolic\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nPeople with asthma have only a modestly increased risk of developing severe Covid-19 and requiring admission to hospital from the illness, finds an analysis of 8.3 million electronic health care records in England led by University of Oxford researchers.
\n \n\n\n \n 19 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nClose monitoring and evaluation as schools reopen crucial to inform ongoing policy
\n \n\n\n \n 3 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nFrom today, the UK\u2019s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
\n \n\n\n \n 16 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nMore people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.
\n \n\n\n \n 25 January 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nUpdate from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
\n \n\n\n \n 15 January 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Cancer\n \n \n \n \n Policy & health systems\n \n \n\n \n\n\n
\n \n\n \n \n \nA new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020.
\n \n\n\n \n 27 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nIn Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.
\n \n\n\n \n 18 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n\n \n\n\n
\n \n\n \n \n \nTwo of the UK\u2019s largest pharmacy chains, LloydsPharmacy and Well Pharmacy, are tasking their branches with helping to find suitable patients for the PRINCIPLE Trial of Covid-19 treatments.
\n \n\n\n \n 3 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nLed by a research team in the Nuffield Department of Primary Care Health Sciences, the University of Oxford will take part in a new pilot scheme to assess the use of Lateral Flow Tests (LFTs), a new COVID-19 test designed to identify asymptomatic individuals with the virus.
\n \n\n\n \n 21 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nEurope\u2019s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
\n \n\n\n \n 21 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nA new risk model, developed by UK researchers to predict a person\u2019s risk of being admitted to hospital and dying from Covid-19 has been published by The BMJ
\n \n\n\n \n 1 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nMore than 1000 people across the UK have signed-up to take part in the UK-wide PRINCIPLE Trial of potential community-based treatments for COVID-19, led by Oxford University.
\n \n\n\n \n 29 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Health Services Research\n \n \n\n \n\n\n
\n \n\n \n \n \nA project looking at video consulting during and beyond the COVID-19 pandemic is funded by The Health Foundation
\n \n\n\n \n 18 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical trials\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead
\n \n\n\n \n 15 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Infection, Respiratory and Acute Care\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers have hailed a \u2018fantastic\u2019 response from more than 1,700 GP practices who have stepped forward to contribute patient data for vital COVID-19 research from the Nuffield Department of Primary Care Health Sciences \u2013 tripling the amount of data available.
\n \n\n